| Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin AR Ahmed, Z Spigelman, LA Cavacini, MR Posner New England Journal of Medicine 355 (17), 1772-1779, 2006 | 574 | 2006 |
| Consensus Conference: A reappraisal of Gaucher disease-diagnosis and disease management algorithms PK Mistry, MD Cappellini, E Lukina, H Özsan, SM Pascual, H Rosenbaum, ... American journal of hematology 86 (1), 110, 2011 | 229 | 2011 |
| Method of monitoring a location of an area of interest within a patient during a medical procedure ZS Spigelman, RH Theriault US Patent 6,119,033, 2000 | 201 | 2000 |
| Systems and methods for targeting a lesion ZS Spigelman, RH Theriault US Patent 6,731,966, 2004 | 198 | 2004 |
| Antiproliferative effects of suramin on lymphoid cells Z Spigelman, A Dowers, S Kennedy, D DiSorbo, M O'Brien, R Barr, ... Cancer research 47 (17), 4694-4698, 1987 | 109 | 1987 |
| Rituximab: a monoclonal antibody to CD20 used in the treatment of pemphigus vulgaris AK El Tal, MR Posner, Z Spigelman, AR Ahmed Journal of the American Academy of Dermatology 55 (3), 449-459, 2006 | 84 | 2006 |
| Safety and efficacy of alternative alglucosidase alfa regimens in Pompe disease LE Case, C Bjartmar, C Morgan, R Casey, J Charrow, JP Clancy, ... Neuromuscular Disorders 25 (4), 321-332, 2015 | 56 | 2015 |
| Treatment of recalcitrant bullous pemphigoid (BP) with a novel protocol: A retrospective study with a 6-year follow-up AR Ahmed, S Shetty, S Kaveri, ZS Spigelman Journal of the American Academy of Dermatology 74 (4), 700-708. e3, 2016 | 55 | 2016 |
| First line treatment of pemphigus vulgaris with a novel protocol in patients with contraindications to systemic corticosteroids and immunosuppressive agents: preliminary … AR Ahmed, T Nguyen, S Kaveri, ZS Spigelman International immunopharmacology 34, 25-31, 2016 | 52 | 2016 |
| Methods and apparatus for performing procedures on target locations in the body MS Kressy, L Greengard, ZS Spigelman, RH Theriault, SG Wadekar, ... US Patent 7,787,936, 2010 | 46 | 2010 |
| Long-term remissions in recalcitrant pemphigus vulgaris AR Ahmed, S Kaveri, Z Spigelman New England Journal of Medicine 373 (27), 2693-2694, 2015 | 44 | 2015 |
| Establishing patient-tailored variability-based paradigms for anti-cancer therapy: Using the inherent trajectories which underlie cancer for overcoming drug resistance Y Ilan, Z Spigelman Cancer Treatment and Research Communications 25, 100240, 2020 | 31 | 2020 |
| 2', 3'-Dideoxyadenosine is selectively toxic for TdT-positive cells Z Spigelman, R Duff, GP BeardSley, S Broder, D Cooney, NR Landau, ... | 24 | 1988 |
| 2′, 3′-dideoxynucleosides: broad spectrum antiretroviral activity and mechanism of action H Mitsuya, JE Dahlberg, Z Spigelman, S Matsushita, RF Jarrett, ... Human retroviruses, cancer, and AIDS: approaches to prevention and therapy …, 1988 | 15 | 1988 |
| Therapeutic method for selectively treating terminal deoxynucleotidyl transferase-positive neoplastic leukemias and lymphomas RP McCaffrey, Z Spigelman US Patent 4,997,818, 1991 | 14 | 1991 |
| Modified radioassay for measuring asialoglycoprotein in serum. R Byrn, P Thomas, P Medrek, Z Spigelman, N Zamcheck Clinical chemistry 30 (10), 1692-1696, 1984 | 8 | 1984 |
| Gastric wall thickening: do not overlook family history J Chenbhanich, MV Malone, Z Spigelman, K Seetharaman The American Journal of Medicine 130 (2), e69-e70, 2017 | 1 | 2017 |
| TDT-POSITIVE NEOPLASTIC-CELLS ARE SELECTIVELY KILLED BY 2'3'DI-DEOXYADENOSINE Z Spigelman, R DUFF, D COONEY, H MITSUYA, S BRODER, N LANDAU, ... CLINICAL RESEARCH 35 (3), A630-A630, 1987 | 1 | 1987 |
| Suramin may be selectively lymphocytotoxic Z SPIGELMAN, A Dowers, S Kennedy, D DISORBO, M OBRIEN, ... CLINICAL RESEARCH 34 (2), A692-A692, 1986 | 1 | 1986 |
| Corrigendum to" First line treatment of pemphigus vulgaris with a novel protocol in patients with contraindications to systemic corticosteroids and immunosuppressive agents … AR Ahmed, T Nguyen, S Kaveri, ZS Spigelman International immunopharmacology 48, 241, 2017 | | 2017 |
